NAD+ and Cellular Energy Metabolism Research
Nicotinamide adenine dinucleotide sits at the centre of cellular metabolism in two distinct roles, and the second one is why it became a research field of its own.
The redox role
In its classical role, NAD+ is an electron carrier. It accepts a hydride during glycolysis, fatty acid oxidation, and the citric acid cycle to become NADH, which delivers electrons to complex I of the electron transport chain. In this capacity NAD+ is recycled rather than consumed, and the NAD+/NADH ratio is a fundamental indicator of cellular redox state that influences the direction of many metabolic reactions.
The consumed-substrate role
NAD+ is also a substrate that is cleaved and consumed by several enzyme families. Sirtuins1, a class of deacylases involved in metabolic and stress-response regulation, require NAD+ and cleave it in the process. PARP enzymes consume NAD+ during DNA damage response signalling. CD38, an ectoenzyme, degrades NAD+ and related nucleotides. Because these enzymes destroy the molecule rather than recycle it, cellular NAD+ must be continuously resynthesised — which makes its availability a genuine variable rather than a constant.
Synthesis and precursors
Cells generate NAD+ through the de novo pathway from tryptophan and, more prominently, through salvage pathways that recycle nicotinamide via nicotinamide phosphoribosyltransferase, a recognised rate-limiting step. Precursor molecules including nicotinamide riboside and nicotinamide mononucleotide2 feed these salvage routes and are widely used as research tools for manipulating cellular NAD+ availability.
What the research examines
Declining tissue NAD+ concentrations have been reported with age across multiple model organisms, and increased CD38 activity is one proposed contributor. A substantial preclinical literature examines the consequences of manipulating NAD+ availability for mitochondrial function and stress resistance in cell and animal models. Human studies of precursor supplementation have generally shown that circulating NAD+ metabolites can be raised, while functional outcomes have been more variable and are the subject of ongoing investigation.
Interpreting the field
The biochemistry is firmly established. The open questions concern which tissues, which enzymes, and which downstream processes are meaningfully limited by NAD+ availability under given conditions — questions that remain genuinely unsettled.
References
- Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141. doi:10.1038/s41580-020-00313-x
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–547. doi:10.1016/j.cmet.2018.02.011
Disclosure. This article is educational and summarises published scientific literature. It is not medical advice, and it does not describe outcomes you should expect. These statements have not been evaluated by the Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease. The products discussed are supplied for laboratory and research use only and are not for human or veterinary use, administration, or consumption. For adults 21 and over.
